Therapeutic use of interleukin-2 mutants
AssigneeUniversity of Southern California
InventorsAlan L. Epstein, Peisheng Hu
Life of this patent
Estimating the term…
Abstract
Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular substitutions within IL-2, particularly within the permeability enhancing peptide region of IL-2 achieve substantial reduction of vasopermeability activity as compared to a wildytpe form of the mutant IL-2 while retaining many of the immune activating properties of IL-2. Invention IL-2 mutants can be used to stimulate the immune system of an animal and may be used in the treatment of various disorders and conditions.
Claims8
A method of decreasing solid tumor size in a cancer patient, said method comprising administering an effective amount of an interleukin-2 (IL-2) mutant with reduced vasopermeability activity compared to a wildtype form of the IL-2 mutant, said mutant being Arg38Trp, wherein said wildtype form of the human IL-2 mutant is human IL-2 and wherein said IL-2 mutant is not linked to an antibody.
Dependencies are inferred from the claim text.